Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: An open label, single arm, phase II trial

Clinical Lymphoma, Myeloma and Leukemia

Volumn 15, Issue 3, 2015, Pages 152-158

  Oki, Yasuhiro ^a   Ewer, Michael S ^a   Lenihan, Daniel J ^b   Fisch, Michael J ^a   Hagemeister, Fredrick B ^a   Fanale, Michelle ^a   Romaguera, Jorge ^a   Pro, Barbara ^a   Fowler, Nathan ^a   Younes, Anas ^a   Astrow, Alan B ^c   Huang, Xuelin ^a   Kwak, Larry W ^a   Samaniego, Felipe ^a   McLaughlin, Peter ^a   Neelapu, Sattva S ^a   Wang, Michael ^a   Fayad, Luis E ^a   Durand, Jean Bernard ^a   Alma Rodriguez, M ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c MAIMONIDES MEDICAL CENTER   (United States)

Author keywords

Anthracycline; Cardiac toxicity; Diffuse large B cell lymphoma; Elderly patients; Pegylated liposomal doxorubicin

Indexed keywords

ASPARTATE AMINOTRANSFERASE; CREATININE; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; MACROGOL DERIVATIVE; MONOCLONAL ANTIBODY; R-CHOP PROTOCOL;

ADULT; AGED; ANEMIA; ANOREXIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATRIOVENTRICULAR BLOCK; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CARDIOTOXICITY; CONGESTIVE HEART FAILURE; CONSTIPATION; DEHYDRATION; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DYSPNEA; EVENT FREE SURVIVAL; FAINTNESS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HEART ATRIUM FIBRILLATION; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOXIA; INSOMNIA; INTENTION TO TREAT ANALYSIS; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; OPEN STUDY; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PNEUMONIA; REVIEW; RIGOR; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; SINGLE BLIND PROCEDURE; THROMBOCYTOPENIA; THROMBOEMBOLISM; URINE RETENTION; VERY ELDERLY; VISION; AGE; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMORBIDITY; DISEASE COURSE; DRUG SUBSTITUTION; KAPLAN MEIER METHOD; LYMPHOMA, LARGE B-CELL, DIFFUSE; METASTASIS; MIDDLE AGED; MORTALITY; TREATMENT OUTCOME;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMORBIDITY; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; DOXORUBICIN; DRUG SUBSTITUTION; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; POLYETHYLENE GLYCOLS; PREDNISONE; TREATMENT OUTCOME; VINCRISTINE;

EID: 84923322401     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2014.09.001     Document Type: Article

References (23)

1. W.H. Wilson Treatment strategies for aggressive lymphomas: what works? Hematology Am Soc Hematol Educ Prog 2013 2013 584 590
2. M.S. Ewer, and S.M. Ewer Troponin I provides insight into cardiotoxicity and the anthracycline-trastuzumab interaction J Clin Oncol 28 2010 3901 3904
3. M. Lotrionte, G. Biondi-Zoccai, and A. Abbate Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity Am J Cardiol 112 2013 1980 1984
4. C. Sarkozy, and B. Coiffier Diffuse large B-cell lymphoma in the elderly: a review of potential difficulties Clin Cancer Res 19 2013 1660 1669
5. T.M. Suter, and M.S. Ewer Cancer drugs and the heart: importance and management Eur Heart J 34 2013 1102 1111
6. 2 in patients with recurrent ovarian and peritoneal cancer Int J Gynecol Cancer 18 2008 223 227
7. R.M. Lang, M. Bierig, and R.B. Devereux Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology J Am Soc Echocardiogr 18 2005 1440 1463
8. B.D. Cheson, S.J. Horning, and B. Coiffier Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas: NCI Sponsored International Working Group J Clin Oncol 17 1999 1244
9. B.D. Cheson, B. Pfistner, and M.E. Juweid Revised response criteria for malignant lymphoma J Clin Oncol 25 2007 579 586
10. B. Coiffier, E. Lepage, and J. Briere CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma N Engl J Med 346 2002 235 242
11. D.D. Von Hoff, M.W. Layard, and P. Basa Risk factors for doxorubicin-induced congestive heart failure Ann Intern Med 91 1979 710 717
12. M. Pfreundschuh, J. Schubert, and M. Ziepert Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60) Lancet Oncol 9 2008 105 116
13. R. Delarue, H. Tilly, and N. Mounier Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial Lancet Oncol 14 2013 525 533
14. A. Aviles, N. Neri, C. Castaneda, A. Talavera, J. Huerta-Guzman, and M. Gonzalez Pegylated liposomal doxorubicin in combination chemotherapy in the treatment of previously untreated aggressive diffuse large-B-cell lymphoma Med Oncol 19 2002 55 58
15. N. Tsavaris, C. Kosmas, and M. Vadiaka Pegylated liposomal doxorubicin in the CHOP regimen for older patients with aggressive (stages III/IV) non-Hodgkin's lymphoma Anticancer Res 22 2002 1845 1848
16. R. Martino, G. Perea, and M.D. Caballero Cyclophosphamide, pegylated liposomal doxorubicin (Caelyx), vincristine and prednisone (CCOP) in elderly patients with diffuse large B-cell lymphoma: results from a prospective phase II study Haematologica 87 2002 822 827
17. C.J. Schmitt, S. Dietrich, A.D. Ho, and M. Witzens-Harig Replacement of conventional doxorubicin by pegylated liposomal doxorubicin is a safe and effective alternative in the treatment of non-Hodgkin's lymphoma patients with cardiac risk factors Ann Hematol 91 2012 391 397
18. A.M. Levine, A. Tulpule, and B. Espina Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma: results of therapy and correlates of response J Clin Oncol 22 2004 2662 2670
19. F. Zaja, V. Tomadini, and A. Zaccaria CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphoma Leuk Lymphoma 47 2006 2174 2180
20. A.M. Levine, A. Noy, and J.Y. Lee Pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone in AIDS-related lymphoma: AIDS Malignancy Consortium Study 047 J Clin Oncol 31 2013 58 64
21. A. Tulpule Multidrug resistance in AIDS-related lymphoma Curr Opin Oncol 17 2005 466 468
22. G. Visani, F. Ferrara, and F. Alesiani R-COMP 21 for frail elderly patients with aggressive B-cell non-Hodgkin lymphoma: a pilot study Leuk Lymphoma 49 2008 1081 1086
23. O. Hequet, Q.H. Le, and I. Moullet Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults J Clin Oncol 22 2004 1864 1871